These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 24011425)

  • 1. Molecular characterization of prostate cancer following androgen deprivation: the devil in the details.
    Barbieri CE; Rubin MA
    Eur Urol; 2014 Jul; 66(1):40-1. PubMed ID: 24011425
    [No Abstract]   [Full Text] [Related]  

  • 2. Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy.
    Rajan P; Sudbery IM; Villasevil ME; Mui E; Fleming J; Davis M; Ahmad I; Edwards J; Sansom OJ; Sims D; Ponting CP; Heger A; McMenemin RM; Pedley ID; Leung HY
    Eur Urol; 2014 Jul; 66(1):32-9. PubMed ID: 24054872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resveratrol inhibits hypoxia-inducible factor-1α-mediated androgen receptor signaling and represses tumor progression in castration-resistant prostate cancer.
    Mitani T; Harada N; Tanimori S; Nakano Y; Inui H; Yamaji R
    J Nutr Sci Vitaminol (Tokyo); 2014; 60(4):276-82. PubMed ID: 25297617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer.
    Siu MK; Chen WY; Tsai HY; Chen HY; Yin JJ; Chen CL; Tsai YC; Liu YN
    Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):172-178. PubMed ID: 28220803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [ASC-J9 for castration-resistant prostate cancer].
    Yamashita S; Arai Y
    Nihon Rinsho; 2014 Dec; 72(12):2126-9. PubMed ID: 25518345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen receptor splice variant 7 in castration-resistant prostate cancer: Clinical considerations.
    Bryce AH; Antonarakis ES
    Int J Urol; 2016 Aug; 23(8):646-53. PubMed ID: 27255944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-182 promotes prostate cancer progression through activating Wnt/β-catenin signal pathway.
    Wang D; Lu G; Shao Y; Xu D
    Biomed Pharmacother; 2018 Mar; 99():334-339. PubMed ID: 29353209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular alterations and emerging targets in castration resistant prostate cancer.
    Lorente D; De Bono JS
    Eur J Cancer; 2014 Mar; 50(4):753-64. PubMed ID: 24418724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SRD5A gene polymorphism in Japanese men predicts prognosis of metastatic prostate cancer with androgen-deprivation therapy.
    Shiota M; Fujimoto N; Yokomizo A; Takeuchi A; Itsumi M; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
    Eur J Cancer; 2015 Sep; 51(14):1962-9. PubMed ID: 26169017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Castration Resistant Prostate Cancer can be Predicted by a DNA Hypermethylation Profile.
    Angulo JC; Andrés G; Ashour N; Sánchez-Chapado M; López JI; Ropero S
    J Urol; 2016 Mar; 195(3):619-26. PubMed ID: 26551297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
    Guo C; Yeh S; Niu Y; Li G; Zheng J; Li L; Chang C
    Cancer Lett; 2017 Jul; 397():133-143. PubMed ID: 28323036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment Sequencing in Metastatic Castration-Resistant Prostate Cancer: A Clinical Commentary.
    Stein CA
    Clin Genitourin Cancer; 2015 Oct; 13(5):407-9. PubMed ID: 26119230
    [No Abstract]   [Full Text] [Related]  

  • 14. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence.
    Coutinho I; Day TK; Tilley WD; Selth LA
    Endocr Relat Cancer; 2016 Dec; 23(12):T179-T197. PubMed ID: 27799360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
    Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
    Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of gene expression of the oncogenic Wnt/β-catenin signaling pathway components in the mouse and human epididymis.
    Wang K; Li N; Yeung CH; Cooper TG; Liu XX; Liu J; Wang WT; Li Y; Shi H; Liu FJ
    Asian J Androl; 2015; 17(6):1006-11. PubMed ID: 26228040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PHF21B overexpression promotes cancer stem cell-like traits in prostate cancer cells by activating the Wnt/β-catenin signaling pathway.
    Li Q; Ye L; Guo W; Wang M; Huang S; Peng X
    J Exp Clin Cancer Res; 2017 Jun; 36(1):85. PubMed ID: 28645312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Molecular biology of castration-resistant prostate cancer].
    Doucet L; Terrisse S; Gauthier H; Pouessel D; Le Maignan C; Teixeira L; Culine S
    Bull Cancer; 2015 Jun; 102(6):497-500. PubMed ID: 26028493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Constitutive Intrinsic Inflammatory Signaling Circuit Composed of miR-196b, Meis2, PPP3CC, and p65 Drives Prostate Cancer Castration Resistance.
    Jeong JH; Park SJ; Dickinson SI; Luo JL
    Mol Cell; 2017 Jan; 65(1):154-167. PubMed ID: 28041912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Numb
    Guo Y; Zhang K; Cheng C; Ji Z; Wang X; Wang M; Chu M; Tang DG; Zhu HH; Gao WQ
    Clin Cancer Res; 2017 Nov; 23(21):6744-6756. PubMed ID: 28751447
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.